TABLE 4
FROM:
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
M Inokuchi, T Yamashita, H Yamada, K Kojima, W Ichikawa, Z Nihei, T Kawano and K Sugihara
BACK TO ARTICLETable 4. Response rate
| n | CR | PR | SD | PD | Response (%) | |
|---|---|---|---|---|---|---|
| Phase II portion | 42 | 0 | 26 | 11 | 5 | 62 |
| Lymph nodes | 25 | 0 | 15 | 8 | 2 | 60 |
| Liver | 12 | 0 | 7 | 3 | 2 | 58 |
| Peritoneum | 13 | 0 | 9 | 2 | 2 | 69 |
| Primary | 16 | 0 | 11 | 3 | 2 | 69 |
| Total | 51 | 1 | 30 | 15 | 5 | 61 |
CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease.
Response rate=number of CR and PR/total number (n).